JP2020511131A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511131A5 JP2020511131A5 JP2019548664A JP2019548664A JP2020511131A5 JP 2020511131 A5 JP2020511131 A5 JP 2020511131A5 JP 2019548664 A JP2019548664 A JP 2019548664A JP 2019548664 A JP2019548664 A JP 2019548664A JP 2020511131 A5 JP2020511131 A5 JP 2020511131A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- population
- cell according
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 59
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 10
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 10
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 2
- 102000053602 DNA Human genes 0.000 claims description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 230000003828 downregulation Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022104262A JP7398518B2 (ja) | 2017-03-08 | 2022-06-29 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2023204311A JP7608580B2 (ja) | 2017-03-08 | 2023-12-04 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2024221238A JP2025038128A (ja) | 2017-03-08 | 2024-12-18 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762468890P | 2017-03-08 | 2017-03-08 | |
| US62/468,890 | 2017-03-08 | ||
| PCT/US2018/021332 WO2018165291A1 (en) | 2017-03-08 | 2018-03-07 | MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104262A Division JP7398518B2 (ja) | 2017-03-08 | 2022-06-29 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511131A JP2020511131A (ja) | 2020-04-16 |
| JP2020511131A5 true JP2020511131A5 (enExample) | 2021-04-08 |
| JP7098648B2 JP7098648B2 (ja) | 2022-07-11 |
Family
ID=63446373
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548664A Active JP7098648B2 (ja) | 2017-03-08 | 2018-03-07 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2022104262A Active JP7398518B2 (ja) | 2017-03-08 | 2022-06-29 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2023204311A Active JP7608580B2 (ja) | 2017-03-08 | 2023-12-04 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2024221238A Pending JP2025038128A (ja) | 2017-03-08 | 2024-12-18 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104262A Active JP7398518B2 (ja) | 2017-03-08 | 2022-06-29 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2023204311A Active JP7608580B2 (ja) | 2017-03-08 | 2023-12-04 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
| JP2024221238A Pending JP2025038128A (ja) | 2017-03-08 | 2024-12-18 | 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10801013B2 (enExample) |
| EP (1) | EP3592845A4 (enExample) |
| JP (4) | JP7098648B2 (enExample) |
| KR (4) | KR102769529B1 (enExample) |
| CN (2) | CN110418839B (enExample) |
| AU (2) | AU2018231193B2 (enExample) |
| CA (1) | CA3053252C (enExample) |
| IL (2) | IL268617B2 (enExample) |
| WO (1) | WO2018165291A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110418839B (zh) | 2017-03-08 | 2023-06-09 | 免疫生物公司 | 用于临床的修饰的NK-92haNK003细胞 |
| JP7241161B2 (ja) * | 2018-08-01 | 2023-03-16 | イミュニティーバイオ、インコーポレイテッド | 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム |
| CA3092709A1 (en) | 2018-10-31 | 2020-05-07 | Nantkwest, Inc. | Elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cells |
| CA3117936A1 (en) * | 2018-11-26 | 2020-06-04 | Immunitybio, Inc. | Il-2 dependent nk-92 cells with stable fc receptor expression |
| CN119040363A (zh) * | 2019-03-15 | 2024-11-29 | 河谷细胞有限公司 | 重组erIL-15 NK细胞 |
| JP7555392B2 (ja) * | 2019-07-26 | 2024-09-24 | ナントクウェスト，インコーポレーテッド | 腫瘍溶解のための有効な治療用製剤としての、抗体を予め負荷したｃｄ１６＋ｎｋ－９２細胞 |
| US11992504B2 (en) * | 2019-11-20 | 2024-05-28 | Immunitybio, Inc. | Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment |
| WO2021116913A1 (en) * | 2019-12-09 | 2021-06-17 | Nantkwest, Inc. | Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| KR20230152783A (ko) | 2020-07-07 | 2023-11-03 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
| US20250262301A1 (en) * | 2020-10-26 | 2025-08-21 | Shoreline Biosciences, Inc. | Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells |
| CN114807237A (zh) * | 2022-05-12 | 2022-07-29 | 广东普罗凯融生物医药科技有限公司 | 一种过表达CD16a的NK细胞的制备方法及其应用 |
| CN119522365A (zh) * | 2022-06-28 | 2025-02-25 | 塞勒普尔责任有限公司 | 用于表征针对细胞疗法的产物的方法 |
| US20250298030A1 (en) * | 2024-03-20 | 2025-09-25 | Immunitybio, Inc. | Compositions and Methods for NK-92 Cells Expressing Native CD16 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0842266A4 (en) * | 1995-08-04 | 1999-07-21 | Gen Hospital Corp | TRANSGENIC PORK AND PORK CELLS HAVING HLA GENES OF MAN |
| TW555562B (en) * | 1996-12-27 | 2003-10-01 | Kirin Brewery | Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof |
| EP1007630B1 (en) | 1997-04-30 | 2006-04-19 | Hans Klingemann | Natural killer cell lines and methods of use |
| US8034332B2 (en) * | 1997-04-30 | 2011-10-11 | Conkwest, Inc. | Interleukin-secreting natural killer cell lines and methods of use |
| CA2289915A1 (en) * | 1997-04-30 | 1998-11-05 | Hans Klingemann | Natural killer cell lines and methods of use |
| WO2006023148A2 (en) | 2004-07-10 | 2006-03-02 | Fox Chase Cancer Center | Genetically modified human natural killer cell lines |
| EP2161339A1 (en) * | 2008-08-29 | 2010-03-10 | F. Hoffmann-La Roche Ag | ADCC with modified NK92 cells |
| EP3273993A4 (en) * | 2015-03-27 | 2018-11-07 | Nantkwest, Inc. | Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer |
| JP2018517415A (ja) | 2015-06-10 | 2018-07-05 | ナントクエスト インコーポレイテッド | がんを処置するための改変ｎｋ−９２細胞 |
| CN110418839B (zh) | 2017-03-08 | 2023-06-09 | 免疫生物公司 | 用于临床的修饰的NK-92haNK003细胞 |
-
2018
- 2018-03-07 CN CN201880016940.6A patent/CN110418839B/zh active Active
- 2018-03-07 CA CA3053252A patent/CA3053252C/en active Active
- 2018-03-07 KR KR1020247001475A patent/KR102769529B1/ko active Active
- 2018-03-07 KR KR1020197028804A patent/KR102533061B1/ko active Active
- 2018-03-07 KR KR1020257004694A patent/KR20250026391A/ko active Pending
- 2018-03-07 IL IL268617A patent/IL268617B2/en unknown
- 2018-03-07 KR KR1020237015931A patent/KR102626748B1/ko active Active
- 2018-03-07 AU AU2018231193A patent/AU2018231193B2/en active Active
- 2018-03-07 WO PCT/US2018/021332 patent/WO2018165291A1/en not_active Ceased
- 2018-03-07 JP JP2019548664A patent/JP7098648B2/ja active Active
- 2018-03-07 EP EP18763512.3A patent/EP3592845A4/en active Pending
- 2018-03-07 US US15/914,665 patent/US10801013B2/en active Active
- 2018-03-07 CN CN202310355496.3A patent/CN116440293A/zh active Pending
- 2018-03-07 IL IL316209A patent/IL316209A/en unknown
-
2019
- 2019-05-28 US US16/424,201 patent/US10774310B2/en active Active
-
2020
- 2020-07-23 US US16/937,370 patent/US11753625B2/en active Active
-
2021
- 2021-09-23 AU AU2021236511A patent/AU2021236511B2/en active Active
-
2022
- 2022-06-29 JP JP2022104262A patent/JP7398518B2/ja active Active
-
2023
- 2023-07-18 US US18/223,338 patent/US12492377B2/en active Active
- 2023-12-04 JP JP2023204311A patent/JP7608580B2/ja active Active
-
2024
- 2024-12-18 JP JP2024221238A patent/JP2025038128A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511131A5 (enExample) | ||
| CN105658789B (zh) | 干细胞微粒和miRNA | |
| ES2927175T3 (es) | Método de producción de micropartículas | |
| CN104321062B (zh) | 干细胞微粒 | |
| ES2705052T5 (es) | Micropartículas de células madre y ARNmi | |
| US20250320306A1 (en) | Methods for production of tissue resident memory-like t cells and use thereof | |
| CN113518821A (zh) | 用于免疫疗法的经修饰的自然杀伤(nk)细胞 | |
| CN115651927A (zh) | 编辑rna的方法和组合物 | |
| JP2024096899A5 (enExample) | ||
| CN118389602B (zh) | 经人工操纵的免疫细胞 | |
| CN104703609A (zh) | 干细胞微粒 | |
| WO2018083700A1 (en) | Mesenchymal stem cells populations, their products, and use thereof | |
| JP2016514953A (ja) | テロメア伸長に関する化合物、組成物、方法及びキット | |
| WO2007099534A3 (en) | Compostions and populations of cells obtained from the umbilical cord and methods of producing the same | |
| DE60334382D1 (de) | Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen | |
| WO2023128862A1 (en) | Method for repairing hair cycle-related genes and method for treating hair cycle-related diseases using mir-520d-5p | |
| US20220041999A1 (en) | Methods to enrich genetically engineered t cells | |
| Walters et al. | Divergent functions of histone acetyltransferases KAT2A and KAT2B in keratinocyte self-renewal and differentiation | |
| EP3521428A1 (en) | PROMOTER OF Hspa5 GENE | |
| US20240024373A1 (en) | Method to Improve Therapeutic Properties of Stem Cells | |
| Xiao et al. | Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity | |
| JP2004290197A5 (enExample) | ||
| CN115087455A (zh) | 用于治疗或预防克罗恩病的组合物和方法 | |
| WO2025088508A1 (en) | Means and methods for genetic modification of uba1 | |
| CA3146799A1 (en) | Tumor immunotherapy using sindbis viral vectors and agonist monoclonal antibodies |